ロード中...
Phase II Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal Cell Carcinoma
BACKGROUND: Patients with sarcomatoid renal cell carcinomas (sRCC) have poor outcomes and limited treatment options. Pre-clinical and clinical data suggest susceptibility to cytotoxic agents and vascular endothelial growth factor-targeted therapies. We designed a phase II trial to evaluate the effic...
保存先:
| 出版年: | Clin Genitourin Cancer |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5809227/ https://ncbi.nlm.nih.gov/pubmed/28870517 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2017.07.028 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|